CNBC's Meg Tirrel Speculates About Gilead's New Acquisiton

CNBC's Biotechnology and Pharmaceuticals reporter Meg Tirrel spoke on

about potential takeover targets for

. She said that the stock has a price to earnings ratio of 10, while its peers trade at a median of 21 and she explained that the reason for such a big discount is uncertainty over what can happen after its hepatitis C drug. So far

had two great acquisitions, Triangle in 2002 and Pharmasset in 2011. With these acquisitions the company became a leader in hepatitis C and HIV markets. The management revealed that the next acquisition would be in the market segments that the company is already active, like liver diseases, HIV, cancer and cardiovascular inflammation. Tirrel shared with the viewers the list of companies that are most discussed as takeover targets on the Wall Street for

. This list includes

,

,

and

. She added that some other smaller companies could find its place on the list.